Immunotherapy plus chemoradiotherapy in cervical cancer management
Mené sur 1 060 patientes atteintes d'un cancer du col de l'utérus de stade localement avancé à haut risque de récidive (durée médiane de suivi : 17,9 mois), cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la sécurité de l'ajout de pembrolizumab à une chiomioradiothérapie
Cervical cancer represents a substantial public health challenge with devastating consequences. Although the disease can be prevented through human papillomavirus (HPV) vaccination and screened using cervical cytology or primary high-risk HPV DNA testing, there are still approximately 600 000 new cases diagnosed worldwide each year and nearly 300 000 needless deaths. 1 In the EU, an estimated 30 447 new cases and 13 437 deaths occurred in 2020. 1 With a mean age of 51 years at recurrence, affected individuals tend to be in the midst of their professional careers and might have small children at home. Accordingly, efforts to improve outcomes before recurrence remain a priority. More than two decades have passed since the National Cancer Institute's Clinical Announcement in 1999 attesting to the survival benefits conferred through platinum-based chemoradiation for locally advanced disease.
The Lancet 2024